Molecular typing of Mycoplasma agalactiae: tracing European-wide genetic diversity and an endemic clonal population

Comparative Immunology, Microbiology and Infectious Diseases
Laurent-Xavier NouvelChristine Citti

Abstract

Mycoplasma agalactiae causes chronic infections in small ruminants and remains endemic in many regions of the world, despite intensive and costly eradication programs. In this study, the innate genomic plasticity of M. agalactiae was exploited to design and assess a combination of molecular epidemiological tools to trace the pathogen in different geographic locations and to understand its emergence or re-emergence after eradication campaigns. For this purpose, two collections of M. agalactiae isolates, representing European outbreaks or localized endemic disease in a single region of France, were subjected to RFLP (Restriction Fragment Length Polymorphism) analyses using two sets of DNA probes (distributed across the genome and specific for the vpma gene locus), and a previously described VNTR (Variable Number Tandem Repeats) analysis. A combination of four genome-specific DNA probes and two VNTRs gave the highest discriminative power. Molecular typing revealed that, while isolates from diverse geographical origins fell into clearly different groups, the endemic disease repeatedly observed in the Western Pyrenees region over the past 30 years has been caused by a unique subtype of M. agalactiae. This indicates that the re-emerg...Continue Reading

References

Nov 1, 1988·The Journal of Hospital Infection·P R Hunter, S H Burge
Apr 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·G M Church, W Gilbert
Dec 20, 2000·Bioinformatics·K RutherfordB Barrell
Aug 30, 2001·Journal of Clinical Microbiology·A M KlevytskaP Keim
Apr 25, 2002·Nucleic Acids Research·Eduardo P C Rocha, Alain Blanchard
Mar 29, 2005·Journal of Molecular Evolution·Francisco J M MojicaElena Soria
Jun 25, 2005·Bioinformatics·Tim J CarverJulian Parkhill
Feb 3, 2007·FEMS Immunology and Medical Microbiology·Alex van Belkum
Mar 24, 2007·Science·Rodolphe BarrangouPhilippe Horvath
May 22, 2007·PLoS Genetics·Pascal Sirand-PugnetChristine Citti
Jun 1, 2007·Nucleic Acids Research·Ibtissem GrissaChristine Pourcel
Feb 6, 2008·Molecular Microbiology·Rohini Chopra-DewasthalyWolfgang Jechlinger
Nov 8, 2008·Bioinformatics·Tim CarverJulian Parkhill
Dec 20, 2008·Science·Luciano A Marraffini, Erik J Sontheimer
Jun 13, 2009·Methods in Molecular Biology·Ibtissem GrissaChristine Pourcel
Jan 9, 2010·Science·Philippe Horvath, Rodolphe Barrangou
Feb 4, 2010·Infection and Immunity·S M SzczepanekS J Geary
Feb 4, 2010·Nature Reviews. Genetics·Luciano A Marraffini, Erik J Sontheimer
Jun 8, 2010·BMC Veterinary Research·Myriam ChazelFrançois Poumarat
Jul 17, 2010·Future Microbiology·Christine CittiEric Baranowski
Mar 5, 2011·Journal of Medical Microbiology·L McAuliffeR J Ellis

❮ Previous
Next ❯

Citations

Dec 12, 2012·Journal of Clinical Microbiology·Jaime Ariza-MiguelMarta Hernández
Feb 20, 2013·Trends in Microbiology·Christine Citti, Alain Blanchard
Aug 7, 2014·Veterinary Medicine International·Amit KumarKuldeep Dhama
Dec 21, 2014·Applied and Environmental Microbiology·Florence TardyChristine Citti
Jul 28, 2020·Genes·Christine CittiLaurent-Xavier Nouvel

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.